Olive oil compound may fight heart disease in early trial

NCT ID NCT07422051

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether erythrodiol, a natural compound in pomace olive oil, can reduce early signs of atherosclerosis (hardening of the arteries). Twenty-two healthy adults will eat high-fat meals with different doses of erythrodiol, then researchers will measure how their bodies process fats and whether it reduces inflammation. The goal is to see if this olive oil component could help prevent heart disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
erythrodiol (a compound in pomace olive oil)
What this could lead to
If it works, this could point toward a dietary approach to reduce early steps of atherosclerosis, potentially lowering heart disease risk.
What could go wrong
This is a very small, early-phase trial in healthy young adults, not patients. It only looks at short-term effects after a meal, so long-term benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROSIS CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Instituto de la Grasa-CSIC

    Seville, 41013, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.